TY - JOUR
T1 - Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction
AU - Wang, Tingting
AU - Gnanaprakasam, J. N.Rashida
AU - Chen, Xuyong
AU - Kang, Siwen
AU - Xu, Xuequn
AU - Sun, Hua
AU - Liu, Lingling
AU - Rodgers, Hayley
AU - Miller, Ethan
AU - Cassel, Teresa A.
AU - Sun, Qiushi
AU - Vicente-Muñoz, Sara
AU - Warmoes, Marc O.
AU - Lin, Penghui
AU - Piedra-Quintero, Zayda Lizbeth
AU - Guerau-de-Arellano, Mireia
AU - Cassady, Kevin A.
AU - Zheng, Song Guo
AU - Yang, Jun
AU - Lane, Andrew N.
AU - Song, Xiaotong
AU - Fan, Teresa W.M.
AU - Wang, Ruoning
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/7/1
Y1 - 2020/7/1
N2 - T cells undergo metabolic rewiring to meet their bioenergetic, biosynthetic and redox demands following antigen stimulation. To fulfil these needs, effector T cells must adapt to fluctuations in environmental nutrient levels at sites of infection and inflammation. Here, we show that effector T cells can utilize inosine, as an alternative substrate, to support cell growth and function in the absence of glucose in vitro. T cells metabolize inosine into hypoxanthine and phosphorylated ribose by purine nucleoside phosphorylase. We demonstrate that the ribose subunit of inosine can enter into central metabolic pathways to provide ATP and biosynthetic precursors, and that cancer cells display diverse capacities to utilize inosine as a carbon source. Moreover, the supplementation with inosine enhances the anti-tumour efficacy of immune checkpoint blockade and adoptive T-cell transfer in solid tumours that are defective in metabolizing inosine, reflecting the capability of inosine to relieve tumour-imposed metabolic restrictions on T cells.
AB - T cells undergo metabolic rewiring to meet their bioenergetic, biosynthetic and redox demands following antigen stimulation. To fulfil these needs, effector T cells must adapt to fluctuations in environmental nutrient levels at sites of infection and inflammation. Here, we show that effector T cells can utilize inosine, as an alternative substrate, to support cell growth and function in the absence of glucose in vitro. T cells metabolize inosine into hypoxanthine and phosphorylated ribose by purine nucleoside phosphorylase. We demonstrate that the ribose subunit of inosine can enter into central metabolic pathways to provide ATP and biosynthetic precursors, and that cancer cells display diverse capacities to utilize inosine as a carbon source. Moreover, the supplementation with inosine enhances the anti-tumour efficacy of immune checkpoint blockade and adoptive T-cell transfer in solid tumours that are defective in metabolizing inosine, reflecting the capability of inosine to relieve tumour-imposed metabolic restrictions on T cells.
UR - http://www.scopus.com/inward/record.url?scp=85088415081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088415081&partnerID=8YFLogxK
U2 - 10.1038/s42255-020-0219-4
DO - 10.1038/s42255-020-0219-4
M3 - Article
C2 - 32694789
AN - SCOPUS:85088415081
VL - 2
SP - 635
EP - 647
JO - Nature Metabolism
JF - Nature Metabolism
IS - 7
ER -